Comment
doi: 10.1136/gutjnl-2020-323668.
Epub 2020 Dec 4.
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
Affiliations
- PMID: 33277346
- DOI: 10.1136/gutjnl-2020-323668
Item in Clipboard
Comment
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
Gut.
2021 Oct.
No abstract available
Keywords: COVID-19; proton pump inhibition.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.Gut. 2021 Jan;70(1):76-84. doi: 10.1136/gutjnl-2020-322248. Epub 2020 Jul 30. Gut. 2021. PMID: 32732368
-
Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis.Gut. 2021 Sep;70(9):1806-1808. doi: 10.1136/gutjnl-2020-323366. Epub 2020 Nov 10. Gut. 2021. PMID: 33172925 Free PMC article. No abstract available.
Similar articles
-
Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study.Gastroenterology. 2021 Apr;160(5):1898-1899. doi: 10.1053/j.gastro.2020.05.098. Epub 2020 Jul 16. Gastroenterology. 2021. PMID: 32682763 Free PMC article. No abstract available.
-
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.Am J Gastroenterol. 2021 Apr;116(4):848-849. doi: 10.14309/ajg.0000000000001008. Am J Gastroenterol. 2021. PMID: 33982973 Free PMC article. No abstract available.
-
Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort.Gut. 2022 Jul;71(7):1447-1450. doi: 10.1136/gutjnl-2021-325701. Epub 2021 Oct 18. Gut. 2022. PMID: 34663578 Free PMC article. No abstract available.
-
Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies.Gastroenterology. 2021 Jun;160(7):2588-2590.e7. doi: 10.1053/j.gastro.2021.02.028. Epub 2021 Feb 17. Gastroenterology. 2021. PMID: 33609504 Free PMC article. Review. No abstract available.
-
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.022. Epub 2022 Dec 1. J Infect. 2023. PMID: 36462586 Free PMC article. No abstract available.
Cited by
-
Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong.BMJ Open Diabetes Res Care. 2021 Jun;9(1):e001950. doi: 10.1136/bmjdrc-2020-001950. BMJ Open Diabetes Res Care. 2021. PMID: 34117050 Free PMC article.
-
Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.ESC Heart Fail. 2022 Apr;9(2):1388-1399. doi: 10.1002/ehf2.13830. Epub 2022 Feb 7. ESC Heart Fail. 2022. PMID: 35132823 Free PMC article.
-
Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.Cancer Med. 2023 Jun;12(11):12299-12315. doi: 10.1002/cam4.5927. Epub 2023 May 6. Cancer Med. 2023. PMID: 37148547 Free PMC article.
-
Efficacy and safety of proton pump inhibitors on cardiovascular events and inflammatory factors in patients with upper gastrointestinal bleeding undergoing dual antiplatelet therapy.Inflammopharmacology. 2024 Jun;32(3):1999-2006. doi: 10.1007/s10787-024-01467-2. Epub 2024 Apr 20. Inflammopharmacology. 2024. PMID: 38642222
-
An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19.Clin Drug Investig. 2021 Mar;41(3):287-289. doi: 10.1007/s40261-021-01007-8. Epub 2021 Feb 19. Clin Drug Investig. 2021. PMID: 33606199 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
